Hyperphagia triggers and accelerates diabetes, and prevents proper dietary control of glycemia. Inversely, the impact of hyperglycemia on hyperphagia and possible mechanistic cause common for these two metabolic disorders in type 2 diabetes are less defined. The present study examined the precise developmental process of hyperglycemia and hyperphagia and explored the alterations in the hypothalamic arcuate nucleus (ARC), the primary feeding and metabolic center, in Goto-Kakizaki (GK) rats with type 2 diabetes and nearly normal body weight. At mid 3 to 4 weeks of age, GK rats first exhibited hyperglycemia, and then hyperphagia and reduced mRNA expressions for anorexigenic pro-opiomelanocortin (POMC) and glucokinase in ARC. Furthermore, [Ca 2+ ]i responses to high glucose in ARC POMC neurons were impaired in GK rats at 4 weeks. Treating GK rats from early 3 to mid 6 weeks of age with an anti-diabetic medicine miglitol not only suppressed hyperglycemia but ameliorated hyperphagia and restored POMC mRNA expression in ARC. These results suggest that the early hyperglycemia occurring in weaning period may lead to impaired glucose sensing and neuronal activity of POMC neurons, and thereby induce hyperphagia in GK rats. Correction of hyperglycemia in the early period may prevent and/or ameliorate the progression of hyperphagia in type 2 diabetes.
Introduction
Hyperphagia or excessive food intake induces and/or accelerates obesity and diabetes (Barrera et al., 2011) , and prevents proper practice of dietary control of body weight and glycemia. Hyperphagia occurs in several animal models of obesity and type 2 diabetes, which include ob/ ob mice, db/db mice, KK-Ay mice, Zucker-fatty rats and OLETF rats (Leedom and Meehan, 1989) . These models exhibit massive obesity due to genetic defects in feeding-and/or glycemia-related molecules, such as leptin and its receptor, agouti-protein, and cholecystokinin receptor. Thus, these are not suitable models for the hyperphagia associated with the common and moderate obesity in humans resulting from life-style and environmental factors. Furthermore, substantial fractions of type 2 diabetes patients, particularly in East Asian population, are non-obese. However, the cause of hyperphagia in non-obese type 2 diabetes is less defined, which is also largely due to lack of suitable animal models of type 2 diabetes without massive obesity.
The Goto-Kakizaki (GK) rats have long been recognized as a spontaneous polygenic type 2 diabetes model with nearly normal body weight (Östenson and Efendic, 2007; Sárközy et al., 2016) . The GK line was established by repeated inbreeding of normal Wistar rats selected by the upper limit of normal distribution of plasma glucose levels in oral glucose tolerance tests (Portha, 2005) . GK rats were shown to exhibit early onset hyperphagia (Maekawa et al., 2006) . Thus, GK rats exhibit both hyperglycemia and hyperphagia at an early stage. Therefore, GK rats may provide a suitable model for studying the impact of hyperglycemia on hyperphagia and a possible mechanistic cause common for them. Hyperglycemia and hyperphagia are known to involve disorders in the central nervous system (Berglund et al., 2013) .
In the present study, we aimed to determine the onset and development of hyperglycemia and hyperphagia in GK rats, and to explore the central causes for these abnormalities. We paid special attention to the arcuate nucleus (ARC) of hypothalamus that regulates both glycemia and feeding, and examined the alteration of neuronal activity and molecular expression. Furthermore, we asked whether the attenuation of hyperglycemia by anti-diabetic medication could ameliorate the downregulation of anorexigenic molecule expressions in ARC and hyperphagia.
Methods

Animals
Male GK rats and Wistar rats were purchased from Japan SLC Co. (Shizuoka, Japan).
The animals were housed in individual cages under controlled temperature (23 ± 1°C), humidity (55 ± 5%) and lighting (light on at 7:30 and off at 19:30 
Measurements of blood glucose levels, body weight and food intake
Blood was taken from a tail vein and blood glucose levels were determined by glucose-oxidase methods using conventional blood glucose self-monitoring device Glucocard Diameter® (Arkray, Kyoto, Japan). Body weight and food intake were measured 5-6 p.m. everyday. For the experiment at weaning period, normal chow, CE-2 pellet food (Japan Clea, Japan), was given, and the blood glucose measured at 5-6 p.m. and 8 a.m. in rats, fed ad-libitum.
Measurements of mRNA expression
After anesthesia by intraperitoneal injection of 25% urethane (0.1 ml/10 g), rats were beheaded and brains were extracted. Slice containing median eminence in rostal-caudal direction was coronally sectioned using a razor degreased by acetone and both sides of arcuate nucleus were cut out with a scalpel. Total RNA was isolated using Trizol (Invitrogen, Carlsbad, CA, USA) and RNase-free DNase (Promega,Madison, WI,USA). First-strand cDNA synthesis was completed using ReverTra Ace (Toyobo, Osaka, Japan). Real-time RT-PCR was performed with SYBR premix Ex taq II polymerase (Takara Bio, Tokyo, Japan) (95°C for 5 s and 60°C for 30 s × 40 cycles) in Thermal Cycler Dice Real Time System TP800 2.10B (Takara Bio). Product accumulation was measured in real time, and the mean cycle threshold (Ct; the cycle during which product is first detected) was determined for replicate samples (n = x to y reactions per primer pair and cDNA sample) run on the same plate. Different cDNA samples were normalized using primer sets to the housekeeping gene glyceraldehydes-3-phosphate dehydrogenase (GAPDH). Expression levels were calculated by the ΔΔCT method. mRNA was measured by real-time PCR as previously reported (Kubista et al., 2006) . Primers were as follows:
Glucokinase (Sequence ID: M25807.1), 5′-TGGATGACAGAGCCAGGATGG-3′ and 5′-ACTTCTGAGCCTTCTG GGGTG-3′.
NPY (Sequence ID: NM_012614.2), 5′-CGCTCTGCGACACTACATCAA-3′ and 5′-GGGCTGGATCTCTTGC CAT-3′.
POMC (Sequence ID: NM_139326.2), 5′-GCCCTCCTGCTTCAGACCTC-3′ and 5′-CTCCGTTGCCTGGAAAC ACGG-3.
GAPDH (Sequence ID: XM_017593963.1), 5′-TCCACGACATACTCAGCAC-3′ and 5′-AACGACCCCTTCATT GAC-3′.
2.4. Administration of α-glucosidase inhibitor, miglitol, in GK-rats Miglitol (Sanwa Kagaku, Nagoya, Japan) was mixed with CE-2 pellet food (Japan Clea, Japan) at 40 mg miglitol per 100 g CE-2 pellet food (Goda et al., 2007; Axen et al., 1999) , and given to GK rats from 21 days old, the time of weaning, to 45 days old. Body weight and food intake were measured at 5-6 p.m. everyday, and ambulatory plasma glucose was measured at 5-6 p.m. and 8 a.m. everyday.
[Ca
2+
] i measurement in single neurons of hypothalamic ARC ARC was cut out bilaterally as described in RT-PCR method section. [Ca 2+ ] i measurement in single neurons was performed as reported previously (Goda et al., 2007) . The dissected tissues were washed with HEPES-buffered Krebs-Ringer bicarbonate buffer (HKRB) (NaCl 129 mM; NaHCO 3 5.0 mM; KCl 3.7 mM; KH 2 PO 4 1.2 mM; CaCl 2 1.8 mM MgSO 4 1.2 mM; HEPES 10 mM; pH 7.4) containing 1 mM glucose, then incubated in the HKRB supplemented with 14 unit/ml papain (Sigma Aldrich, St Lewis, USA), 0.015 mg/ml deoxyribonuclease II-TypeIV (Sigma Aldrich), 0.75 mg/ml bovine serum albumin (Sigma Aldrich), and 0.7 mM L-Cysteine (Sigma Aldrich) for 14 min at 36°C in a water bath with shaking 40 times per minute. After the enzyme treatment, the tissues were triturated by gentle pipetting to disperse into single neurons. Cell suspension was centrifuged at 700 rpm for 5 min, and the pellet was resuspended in HKRB and the single neurons in the suspension were distributed onto coverslips in dishes. After incubation for 30 min at 30°C in the moist chamber with 100% humidity, the dishes were placed at room temperature for up to 6 h in the same chamber until use. Cells were incubated with 2 μM fura-2/AM, a calcium indicator, (Dojin Kagaku, Kumamoto, Japan) for 30 min. Then coverslips with single neurons were mounted in chamber and set on the stage of inverted microscope (Eclipse TE300, Nikon, Tokyo, Japan) with thermostat, and superfused with HKRB containing 1 mM glucose at 1 ml/ min at 32°C. ] i levels in the pre-stimulatory and post-stimulatory states are different, the average value was used. When Δ ratio (peak ratiobaseline ratio) was ≧50% of baseline ratio during perfusion with 5 mM glucose, it was considered the glucose response. Glutamate (0.1 mM) was administered at the end of [Ca 2+ ] i recording to check the healthiness of cells.
Immunocytochemical staining of POMC neurons
After [Ca 2+ ] i measurements, the cells were fixed with 4% paraformaldehyde overnight for immunocytochemistry (Kohno et al., 2003) . Cells were rinsed three times with PBS for 5 min each and pretreated with 3% H 2 O 2 in PBS for 10 min. After washing with PBS 3 times, cells were treated with blocking solution (10% normal goat serum NGS in 1% bovine serum albumin (BSA) in PBS) for 30 min at room temperature. Then cells were incubated with primary antiserum to POMC (from Shizuoka University (Tanaka and Kurosumi, 1992; Kohno et al., 2011) ) diluted 1:4000 in PBS containing 1% BSA for overnight at 4°C. The antiserum was then rinsed with PBS and incubated with biotinylated secondary antibody raised against rabbit IgG (Vector Laboratories Inc., Burlingame, CA; diluted 500-fold in 1% BSA/PBS) for 30 min at room temperature. The secondary antibody was then rinsed 3 times with PBS for 5 min each, and the cells were incubated with avidin-peroxidase complex (ABC kit; Vector) for 30 min. Then ABC reagent was removed and cells were rinsed again, and color was developed with 3,3-diaminobenzidine (DAB ]i was recorded were correlated with the corresponding immunocytochemical results.
Statistical analysis
Experimental results between two groups were examined by Welch t-test, and between three groups by Bonferroni/Dunn test. For the incidence of POMC immnunoreactive cells expressed by percentage in Fig. 3E and F, chi-square tests were used. Repeated measure two-way analyses of variance (ANOVA) were performed on day-to-day profiles of plasma glucose, daily food intake, body weight, and daily food intake per body weight for weaning stage experiments (Fig. 1A-D) , and for miglitol experiments (Fig. 4A-D and G-J). If significant differences exist between rat groups among these parameters, then multiple comparison tests (Tukey's method) was added on these parameters. Making the first time points of experiment as the standard, the time points when significant difference between groups existed were given asterisk (p < .05) and sharp (p < .01) in Figs. 1A, C, and D and 4G and J. Simple linear regression analysis was performed to check the statistical relations between cumulative food intake at early 4 to late 5 weeks and averaged ambulatory blood glucose levels at about 8 a.m. and 5-6 p.m. in control and miglitol-treated Wistar and GK rats at early 4 to late 5 weeks. All results except baseline data in Wistar and GK rats aged 3-4 week were shown as mean and standard error. Baseline data were displayed as mean and standard deviation. p < .05 was considered significantly different. Statistical analyses except two-way repeated ANOVA and multiple comparison tests were made using Stata SE® ver.12 (StataCorp LP, College Station, TX, USA). Two-way repeated ANOVA and multiple comparison tests were done with IBM SPSS Statistics ver. 22 (International Business Machines Corporation, NY, USA).
Results
Changes in food intake and blood glucose levels in early ages
At early 3 weeks, several baseline parameters were not different betweeen Wistar vs. GK rats; daily food intake 6.92 ± 0.35 vs. Changes in ambulatory blood glucose levels, food intake and body weight in GK rats aged 3-4 weeks. Blood glucose levels (A), daily food intake (B), body weight (C), food intake per body weight (D) during 3-4 weeks of age were presented in line graphs. Sharp mark indicated p < .05. Average plasma glucose (E) and cumulative food intake per body weight (F) during the same period were shown in bar graph.
6.91 ± 0.68 g/day (p = 0.51), body weight 43.21 ± 1.67 vs. 41.74 ± 3.14 g (p = 0.19), and daily food intake per body weight 0.16 ± 0.01 vs. 0.17 ± 0.01 g/day (p = 0.17). In contrast, plasma glucose in GK rats was significantly higher than in Wistar rats at early 3 weeks (Wistar 119.60 ± 11.06 vs. GK 156.00 ± 9.51 mg/dL (p < .01)). From early 3 weeks ambulatory plasma glucose, measured at the beginning (around 8 a.m.) and end of light phase (5-6 p.m.), continued to be significantly high in GK rats, compared to Wistar rats at the same age (Fig. 1A, p < .01 ). Daily food intake in GK rats was similar to or rather smaller than that in Wistar rats from late 3-weeks to late 4 weeks (Fig. 1B , p = 0.12). Body weight was slightly but significanly lower than GK rats from late 3 to late 4 weeks (Fig. 1C , p < .05). Consequently, daily food intake per body weight, though declining with age, continued to be significantly higher in GK rats than in Wistar rats from late 3 weeks to late 4 weeks (Fig. 1D , p < .05).
Average plasma glucose and cumulative food intake in 3-4 weeks were significantly increased in GK compared to Wistar rats ( Fig. 1E and F) .
Changes in mRNA expressions in ARC in early ages
At 3 weeks of age, mRNA expressions for glucokinase, POMC and NPY in the arcuate nucleus (ARC) in GK rats were unaltered, compared to Wistar rats (p = 0.50, 0.27, and 0.96, respectively) ( Fig. 2A-C) . At 4 weeks, GK rats exhibited significantly reduced mRNA expressions for glucokinase (p < .05) and POMC (p < .05), but not for NPY (p = 0.39), compared to Wistar rats (Fig. 2D, E, F ] i in single ARC neurons of Wistar and GK rats ( Fig. 3A,B; left), and a substantial fraction of these glucose-excited (GE) neurons were subsequently proved to be immunoreactive (IR) to POMC by immunocytochemistry ( Fig. 3A, B; right). The amplitude of [Ca 2+ ] i responses to 5G in GE neurons in GK rats was much lower than that in Wistar rats (GK, 1.05 ± 0.05 vs. Wistar, 1.58 ± 0.08) (Fig. 3C ), in accordance with reduced expression of glucokinase in ARC of GK rats (Fig. 2D) . Furthermore, the amplitude of [Ca 2+ ] i response to 5G in POMCeIR neurons was significantly lower in GK than Wistar rats (GK, 1.08 ± 0.09 vs. Wistar, 1.60 ± 0.13) (Fig. 3D) . The fraction of POMCeIR neurons in ARC neurons tended to be lower in GK rats (GK, 22.6% vs. Wistar, 28.7%) (Fig. 3E) . Moreover, the incidence of POMC neurons among GE-neurons was further lower in GK rats (21.2%) than Wistar rats (49.2%) (Fig. 3F) . Thus, the reduction of POMC neuron fraction occurred more drastically in GE neurons than in all ARC neurons (Fig. 3E vs. F) , showing that the POMC expression decreased preferentially in GE neurons.
Effect of treatment with anti-diabetic medicine on hyperglycemia and hyperphagia in weaned Wistar and GK rats
To explore whether the hyperglycemia could serve as a cause for the hyperphagia and POMC reduction in GK rats, Wistar and GK rats were treated with α-glucosidase inhibitor miglitol, an anti-diabetic agent, from early 3 to mid 6 weeks of age (Fig. 4 A-D, G-J). The results of twoway repeated ANOVA between miglitol-treated and vehicle groups during experiment period of 3-6 weeks in GK rats were p = .04 for plasma glucose, 0.52 for daily food intake, 0.05 for body weight, and < 0.01 for daily food intake per body weight. Those in Wistar rats were p = 0.69, 0.62, 0.81 and 0.11. The treatment with miglitol (40 mg per 100 g CE-2 pellet food) mildly, but signifcantly lowered average ambulatory plasma glucose levels measured at 5-6 p.m. in GK rats (Fig. 4G , p < .05; K, p < .05), while it had no effects in Wistar rats (Fig. 4A , p = 0.69; Fig. 4F , p = 0.51). This treatment also mildly, but significantly reduced food intake per body weight in GK rats (Fig. 4J , p < .01; Fig. 4L , p < .05). Body weight tended to increase by miglitol treatment, though it did not reach statistical significant level (Fig. 4I , p = 0.053). From 3 weeks 2 day to 3 weeks 7 day, daily food intake and body weight appeared to exhibit no change, but daily food intake slightly decreased and body weight slightly increased by miglitol 
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treatment (Fig. 4H, I ). Consequently, daily food intake per body weight significantly decreased by migltol administration during this period (Fig. 4J , p < .01). Thus, this treatment appeared to reduce both plasma glucose and food intake in hyperglycemic state. We analyzed the relationship between plasma glucose and food intake measured at the same time of 5-6 p.m. in both untreated and treated GK rats at early 4 to late 5 weeks of age. Adjusted regression coefficient of simple linear regression analysis between cumulative food intake per body weight and average ambulatory plasma glucose levels was 0.3373, showing statistically significant relationship (p < .05) (Fig. 5) . Following miglitol administration, POMC mRNA expression in ARC in GK rats was significantly elevated at 6 weeks compared to untreated GK rats (p < .05), while mRNA expressions for glucokinase and NPY were not changed (p = 0.89 and p = 0.79) (Fig. 6 ).
Discussion
The present study demonstrated that GK rats, compared to control Wistar rats, started to display hyperglycemia, hyperphagia, and alterations in the ARC at the specific developmental stage of 3 to 4 weeks. The alterations in the ARC included reduced mRNA expressions for POMC and glucokinase, reduced POMC neuron number, and impaired [Ca 2+ ]i responses to high glucose in POMC neurons.
Treating GK rats at early 3 to mid 6 weeks of age with an anti-diabetic medicine miglitol partially suppressed hyperglycemia, which was accompanied by amelioration of hyperphagia during this period and restoration of POMC mRNA expression in ARC at 6 weeks. These results suggest that in weaning stage of GK rats, hyperglycemia may induce and/or accelerate the ARC POMC down-regulation and hyperphagia, and that down-regulation of ARC POMC may underlie hyperphagia. It is also suggested that the reduced glucokinase activity in ARC may be responsible for the impaired response to glucose of POMC neurons. We found increased food intake in the weaning stage of GK rats. It was reported that food intake was reduced in GK rats aged three months (Zhao et al., 2013) . We also previously reported that hyperphagia and NPY overexpression ceased at 15 weeks of age (Maekawa et al., 2013) . These previous and present findings taken together suggest that young to adult hyperphagia is reversed to hypophagia in GK rats at around 3-4 months. A recent study on gene expression profiles in the hypothalamus of GK rats using transcriptome analysis reported that food intake per body weight was increased and POMC expression in the hypothalamus was reduced from 8 weeks compared to Wistar rats (Meng et al., 2016) . We here report similar changes at a much earlier stage of mid 3 to 4 weeks. This variance in the onset of the POMC downregulation could be related to differences in the sampling sites (ARC vs. whole hypothalamus), assay methods, and GK rat lineages used in the two studies. At the molecular/cellular level, we found reductions in the ARC mRNA expressions for glucokinase and POMC and in the ARC POMC neuron response to glucose in GK rats at 4 weeks, which were accompanied by hyperglycemia. These results suggest that the glucose metabolism via glucokinase in ARC plays a role in maintenance of POMC neuron activity. This notion appears to be supported by previous reports. It was documented that the POMC neurons in ARC, an area located close to the median eminence equipped with incomplete bloodbrain barrier, respond to the change in ambient glucose fluctuations (Belgardt et al., 2009 ). Glucokinase acts as the rate-limiting step in the central and peripheral glucose sensing (Levin, 2006) , and plays an important role in the control of glucose homeostasis and feeding ] i response amplitudes to high glucose are reduced in GK rats POMC neurons (1.05 ± 0.05, n = 59) compared to those of Wistar rats (1.58 ± 0.08, n = 118). D, [Ca 2+ ] i response amplitudes to high glucose in POMCeIR neurons are reduced in GK rats (1.08 ± 0.09, n = 98) compared to Wistar rats (1.60 ± 0.13, n = 30). E, Incidence of POMCeIR neurons in ARC neurons is reduced in GK rats (212 of 938 neurons; 22.6%) compared to Wistar rats (158 of 550 neurons; 28.7%). F, Incidence of POMCeIR neurons in 5 mM glucose-responsive ARC neurons is reduced in GK rats (25 of 118 neurons; 21.2%) compared to Wistar rats (29 of 59 neurons; 49.2%).
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Neuropeptides xxx (xxxx) xxx-xxx behavior by the central nervous system (Stanley et al., 2016) . It was reported that adenovirus-mediated suppression of hypothalamic glucokinase reduces the response of POMC mRNA expression to intracerebroventricular (i.c.v.) injections of glucose (Uranga et al., 2017) , and that POMC mRNA is down-regulated in glucokinase knockout mice (Yang et al., 2007) . Disrupted glucose sensing in glucose-excited POMC neurons leads to impaired glucose tolerance (Parton et al., 2007) . Activity of glucokinase in ARC decreases in diabetes animal model (Nishio et al., 2006) . Whether the dysregulation of glucose-excited POMC neurons in ARC, found in GK rats, could be the general property of type 2 diabetes remains to be determined. The results of this study have demonstrated that hyperglycemia precedes hyperphagia in weaning stages in GK rats. These phenotypes could be initiated and/or augmented at least partly by down-regulation of the ARC POMC, a neuropeptide that inhibits feeding and improves glycemia. Furthermore, miglitol treatment partially attenuated hyperglycemia, which was accompanied by partial restoration of POMC expression without influence on the expression of glucokinase. The results suggest that hyperglycemia induces and/or accelerates the POMC down-regulation. It was reported that in Sprague-Dawley rats receiving streptozotocin, POMC mRNA expression was reduced to 20% of control, and insulin treatment partially restored it to 50% in accordance with the amelioration of hyperglycemia (Havel et al., 2000) . Moreover paternal hyperglycemia predisposes offspring to developing obesity, which is possibly associated with dysfunction of POMC neurons in ARC (Shi et al., 2017) . Although the underlying mechanisms remain unclear, we speculate a mechanism, from the systemic point of view, that both hyperglycemia and hyperphagia elevate the glucose concentration in ARC in a long-term, and thereby produce glucose insensitivity or toxicity to down-regulate POMC neurons, and that the down-regulation of POMC signaling aggravates hyperglycemia and hyperphagia. However, our speculation that elevated glucose concentration in the brain down-regulates the ARC POMC neurons definitely remains to be confirmed by further studies.
In this study, attenuation of hyperglycemia by miglitol treatment also ameliorated hyperphagia. Furthermore, positive correlation between the blood glucose level and food intake was observed in miglitoltreated and untreated GK rats. Miglitol had no effect on glycemia and 3w2d  3w3d  3w4d  3w5d  3w6d  3w7d  4w1d  4w2d  4w3d  4w4d  4w5d  4w6d  4w7d  5w1d  5w2d  5w3d  5w4d  5w5d  5w6d  5w7d   100   110   120   130   140   3w2d  3w3d  3w4d  3w5d  3w6d  3w7d  4w1d  4w2d  4w3d  4w4d  4w5d  4w6d  4w7d  5w1d  5w2d  5w3d  5w4d  5w5d  5w6d Age ( 3w1d  3w2d  3w3d  3w4d  3w5d  3w6d  3w7d  4w1d  4w2d  4w3d  4w4d  4w5d  4w6d  4w7d  5w1d  5w2d  5w3d  5w4d  5w5d  5w6d  5w7d   5   7   9   11   13   15   3w2d  3w3d  3w4d  3w5d  3w6d  3w7d  4w1d  4w2d  4w3d  4w4d  4w5d  4w6d  4w7d  5w1d  5w2d  5w3d  5w4d  5w5d p=0.31 Fig. 4 . Treatment with anti-diabetic medicine, miglitol, decreased plasma glucose levels and food intake in GK but not Wistar rats. A-L, Daily profiles of plasma glucose (A, G), food intake (B,H), body weight (C,I) and food intake per body weight (D,J), and average plasma glucose levels (E,K) and cumulative food intake per BW (F,L) during treatment with miglitol (40 mg per 100 g CE-2 pellet food) from early 4 to late 5 weeks of age in Wistar (A-F) and GK rats (G-L) (n = 5 for each group). Sharp mark and asterisk in daily profiles indicated p < .05 and p < .01 respectively.
food intake in Wistar rats. These results suggest that correction of hyperglycemia may ameliorate overeating in type 2 diabetes. However, at the dose used in this study, the suppressive effect of miglitol on food intake was somewhat larger than that on glycemia in GK rats at 3-6 weeks. The relatively larger effect on food intake could be mediated by the reported action of miglitol to release GLP-1, a potent anorexigenic hormone. This notion is supported by previous report in GK rats that ileal transposition, the surgical procedure to enhance GLP-1 secretion, lead to elevation of hypothalamic POMC concentration and reduction of body weight (Chen et al., 2011) . The present study demonstrated down-regulation of glucose-responsiveness and POMC neuron activity in ARC in the early developmental stage, possibly serving as the common cause for hyperglycemia and hyperphagia. Considerable fraction of patients with type 2 diabetes suffers from poor control of both glycemia and appetite. Hence, counteracting the down-regulation of glucose-responsiveness and POMC neuron activity in ARC could provide a novel avenue to treat both hyperglycemia and hyperphagia in type 2 diabetic patients. In fact, it has recently been reported that POMC gene delivery ameliorates obesity and glucose intolerance in rats aged 22 months (Li et al., 2005) . 3w3d  3w4d  3w5d  3w6d  3w7d  4w1d  4w2d  4w3d  4w4d  4w5d  4w6d  4w7d  5w1d  5w2d  5w3d  5w4d  5w5d  5w6d  5w7d  6w1d  6w2d  6w3d   100   120   140   160   180   3w1d  3w2d  3w3d  3w4d  3w5d  3w6d  3w7d  4w1d  4w2d  4w3d  4w4d  4w5d  4w6d  4w7d  5w1d  5w2d  5w3d  5w4d  5w5d  5w6d  5w7d  6w1d 3w2d  3w3d  3w4d  3w5d  3w6d  3w7d  4w1d  4w2d  4w3d  4w4d  4w5d  4w6d  4w7d  5w1d  5w2d  5w3d  5w4d  5w5d  5w6d  5w7d  6w1d  6w2d  6w3d A. Ando et al.
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